undamentalytics Newsletter
Sign in

Avalo Therapeutics, Inc. cash flow statement

In fiscal 2025, Avalo Therapeutics, Inc.'s operations generated −$51.5m of cash; it spent $0 on capital projects, leaving free cash flow of −$51.5m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Cash from operations−10−1513−3−19−41−71−27−31−49−51
Depreciation and amortisation00054220000
Stock-based pay021237883614
Capital spending00010000000
Free cash flow−10−1513−4−19−41−71−27−31−49−51
Free cash flow after stock pay−11−1611−6−22−47−79−34−34−55−65
Shares issued022093529032015

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: AVTX vs CRDFAVTX vs CRVOAVTX vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Avalo Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Avalo Therapeutics, Inc.